Elutia Inc. (ELUT)
After hours:
| Previous close | 4.2400 |
| Open | 4.3200 |
| Bid | 4.6100 x 100 |
| Ask | 5.0900 x 100 |
| Day's range | 4.3100 - 4.9900 |
| 52-week range | 1.1000 - 4.9900 |
| Volume | |
| Avg. volume | 45,761 |
| Market cap | 136.524M |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4100 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.50 |
Simply Wall St.Individual investors in Elutia Inc. (NASDAQ:ELUT) are its biggest bettors, and their bets paid off as stock gained 16% last week
Key Insights The considerable ownership by individual investors in Elutia indicates that they collectively have a...
GlobeNewswireElutia Announces $13.26 Million Registered Direct Offering
SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company’s Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The pre
- GlobeNewswire
Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators
EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market EluPro also granted clearance for indications beyond CIEDs, including neurostimulators and neuromodulators used for pain management, epilepsy, incontinence, and sleep apnea SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced th
